Litcius/Paper detail

Nanocarrier-Based Approaches to Combat Chronic Obstructive Pulmonary Disease

Tarun Virmani, Girish Kumar, Reshu Virmani, Ashwani Sharma, Kamla Pathak

2022Nanomedicine34 citationsDOI

Abstract

Abnormalities in airway mucus lead to chronic disorders in the pulmonary system such as asthma, fibrosis and chronic obstructive pulmonary disease (COPD). Among these, COPD is more prominent worldwide. Various conventional approaches are available in the market for the treatment of COPD, but the delivery of drugs to the target site remains a challenge with conventional approaches. Nanocarrier-based approaches are considered the best due to their sustained release properties to the target site, smaller size, high surface-to-volume ratio, patient compliance, overcoming airway defenses and improved pharmacotherapy. This article provides updated information about the treatment of COPD along with nanocarrier-based approaches as well as the potential of gene therapy and stem cell therapy to combat the COPD.

Topics & Concepts

COPDNanocarriersMedicinePulmonary diseaseIntensive care medicineAirwayAsthmaPharmacotherapyMucusInternal medicineDrugPharmacologySurgeryBiologyEcologyInhalation and Respiratory Drug DeliveryNeonatal Respiratory Health ResearchChronic Obstructive Pulmonary Disease (COPD) Research
Nanocarrier-Based Approaches to Combat Chronic Obstructive Pulmonary Disease | Litcius